Denosumab-induced osteonecrosis of external auditory canal
| Autor: | Takeshi Tsutsumi, Yoshiyuki Kawashima, Iichiroh Onishi, Taro Fujikawa, Taku Ito, Takamori Takeda, Masaru Yokomura |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
2019-20 coronavirus outbreak
medicine.medical_specialty Osteoporosis Bone erosion Auditory canal Humans Medicine Major complication Aged 80 and over Bone Density Conservation Agents business.industry Osteonecrosis General Medicine medicine.disease Surgery Conservative treatment Denosumab Otorhinolaryngology Radical mastoidectomy Female Tomography X-Ray Computed business Ear Canal medicine.drug |
| Zdroj: | Auris Nasus Larynx. 48:1199-1203 |
| ISSN: | 0385-8146 |
| DOI: | 10.1016/j.anl.2020.07.007 |
| Popis: | Denosumab is the world's first human monoclonal antibody for the treatment of osteoporosis and shares an active pathway with bisphosphonates, strongly suppressing osteoclast activities. This is the first case report describing a possible relationship between the development of osteonecrosis of external auditory canal and denosumab administration. We herein report an 81-year-old woman diagnosed with left osteonecrosis of external auditory canal who had a history of denosumab administration. She underwent left radical mastoidectomy due to being refractory to conservative treatment. No major complications or recurrence were observed in the left ear after surgery, but bone erosion in the right ear has continued to progress slowly despite the cessation of denosumab administration. Otolaryngologists should be aware of the association between osteonecrosis of external auditory canal and denosumab administration and consider performing long-term observation even after cessation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect